Topic
1 story, newest first.
The U.S. Food and Drug Administration has approved daraxonrasib, branded as Rasonque, for metastatic pancreatic cancer. In trials, patients taking the drug lived a median of 13.2 months, compared to 6.7 months on chemotherapy.
